Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: LANCE B who wrote (20007)	9/29/1999 1:19:00 PM
From: John R Resseger	Respond to of 25711

In the second quarter of 1998, Antex initiated a drug development program with the goal to develop broad-spectrum and specific-agent antibiotics. The strategy is to leverage the Company's platform technologies and vaccine research by identifying novel targets, discovering new chemical entities, and enhancing currently marketed antibiotics. Novel targets have been identified and validated, and screening assays are being developed and validated. Four series of new chemical entities have been discovered. Patent and literature searches indicate these compounds are novel and proprietary. Based on the substitutions that can be made on the four core structures, Antex has a position on over 10 million new proprietary compounds. Virtual screening has been used to identify the initial 200 new chemical entities that will be synthesized and screened.